Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sepracor: Beyond Meridia

While Knoll Pharmaceutical Co. markets its Meridia sibutramine neurotransmitter reuptake inhibitor to treat obesity, the active ingredients may have more widespread potential. To pursue that potential,

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE